DFM STUDENT SYLLABUS - Flipbook - Page 23
Value of Multi-Tissue Antibody Screening
355
Identification of Polyautoimmunity Risk
355
Early Intervention Opportunity
355
Monitoring Treatment Efficacy
355
Who Should Consider Array 5
355
Family History of Autoimmunity
355
Early Symptoms Without Diagnosis
356
Established Autoimmune Disease
356
Intestinal Permeability
356
Unexplained Inflammatory Symptoms
356
Conditions Where Array 5 is Especially Valuable
357
Thyroid Autoimmunity
357
Type 1 Diabetes
357
Rheumatoid Arthritis
357
Multiple Sclerosis
357
Systemic Lupus Erythematosus (SLE)
357
Inflammatory Bowel Diseases
358
Autoimmune Hepatitis and Biliary Conditions
358
Can Early Autoimmune Reactivity Be Reversed?
358
Autoimmune Reversibility Factors
358
Stage of Autoimmune Process
358
Antibody Titers and Patterns
358
Underlying Trigger Identification
359
Comprehensive Intervention Strategies
359
Intestinal Barrier Healing
359
Environmental Trigger Removal
359
Immune Modulation
359
Anti-Inflammatory Protocol
359
Success Rates and Timelines
360
Antibody Reduction Timelines
360
Symptom Improvement
360
Long-Term Outcomes
360
Clinical Integration of Array 5 with Other Testing
360
22
